NCT00413764已完成3 期
A Multicenter, Randomized, Double-Blind, Double Dummy Trial to Compare the Effects Tibolone and Transdermal Continuous Combined Estradiol/Norethisterone on Sexual Desire and Arousal in Postmenopausal Women With Sexual Dysfunction
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 358
- 主要终点
- Compare the effect of tibolone (2.5 mg) to transdermal E2/NETA (50/140 mcg) on the vaginal bleeding and spotting rate in healthy postmenopausal women with sexual dysfunction.
研究概览
简要总结
Tibolone has been registered for treatment of menopausal symptoms. It is, however, not known what the effects are of tibolone in postmenopausal women diagnosed with sexual dysfunction. This is important because there is currently no approved treatment of libido problems in postmenopausal women. Therefore, the primary aim of this study was to compare the effects of tibolone with an estrogen/progestogen skin patch in postmenopausal women diagnosed sexual dysfunction.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 48 Years 至 68 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Physically and mentally healthy postmenopausal women, >=48 and <=68 years of age, with an intact uterus.
- •Women were to suffer from decreased satisfactory sexual activity compared to younger age and sexual problems were not to be considered caused by relationship/partner problems. The decreased sexual functioning was to result in sexually related personal distress as confirmed by the FSDS (score =15).
- •An affirmative answer was to be given to the following questions: (a) In previous years did you find sexual activity satisfying? (b) Has there been a decline in your satisfaction with sexual activity? (c) Are you satisfied with your partner as a friend?
- •All subjects were to have an established sexual relationship of at least 6 months duration prior to screening.
- •Women were to be sexually active.
- •Normal mammography within 6 months prior to randomization.
- •Body mass index >18 and <=32 kg/m
- •Voluntary written informed consent
排除标准
- •Any unexplained abnormal uterine bleeding
- •Double layer endometrial thickness >4 mm
- •Tibolone or transdermal E2/NETA use within 3 months prior to screening
- •Progestogen implants or injections and estrogen/progestogen injectable therapy within 6 months prior to screening
- •Use of intra-uterine progestogen
- •Unsuccessful previous treatment with androgens or compounds known to enhance androgenic activity
- •Current successful treatment with androgens, without applying the applicable washout period of 3 months prior to screening
- •Any previous or current unopposed estrogen administration, prior use of estrogen pellets or tamoxifen citrate (previous low dose vaginal estrogen-only applications are allowed)
- •Use of anti -androgens within the preceding 5 years prior to screening.
- •Women with significant organic disorder of sexual dysfunction or a partner with sexual dysfunction
- •Women who had early onset sexual dysfunction (>15 years prior to menopause)
- •Women suffering from androgenic alopecia, acne or hirsutism
- •Women suffering from illnesses influencing sexuality
- •Women using medication influencing sexuality
- •Moderate to severe depression
- •Current or prior use of antidepressant within 8 weeks prior to screening
- •Major gynecological surgery in the preceding 3 months
- •Any serious disease or disorder; or any endocrine disorder with systemic disease which would have impaired overall health and well being (controlled hypo/hyperthyroidism and diabetes mellitus Type II was allowed)
- •History or presence of severe psychiatric illness and/or any addictions to drugs, medication or alcohol in the past 3 years
- •Diseases for which exogenous hormonal steroids were contraindicated.
- •History or presence of any malignancy, except successfully treated non-melanoma skin cancers
- •History or presence of cardiovascular or cerebrovascular conditions, thrombosis or thromboembolic disorders
- •History or presence of liver, gallbladder or renal disease, epilepsy or classical migraine headaches
- •Uncontrolled hypertension
- •Women with abnormal cervical smear results
- •History or presence of breast cancer, suspicious breast lump or mammographic abnormality
- •Known hypersensitivity to any of the ingredients of the trial medication.
- •Non-compliance with the screening diary
- •Current use of raloxifene, clonidine, veralipride, phytoestrogen extracts
- •Drugs known to interfere with the pharmacokinetics of the steroids
- •Use of investigational drugs within the past 60 days
- •Any disease or condition that was clinically relevant and which, in the opinion of the investigator, would have jeopardized the subject's well being during the course of the trial
研究组 & 干预措施
1
Experimental
tibolone
干预措施: tibolone (Drug)
2
Active Comparator
transdermal continuous combined E2-NETA (estradiol-norethisterone)
干预措施: estradiol-norethisterone (Drug)
结局指标
主要结局
Compare the effect of tibolone (2.5 mg) to transdermal E2/NETA (50/140 mcg) on the vaginal bleeding and spotting rate in healthy postmenopausal women with sexual dysfunction.
时间窗: Week 13-24 of the in treatment period
Compare the effect of tibolone to E2/NETA on sexual functioning in healthy postmenopausal women with sexual dysfunction.
时间窗: Week 8-12 and Week 20-24 of the in-treatment period.
次要结局
- Compare the effects of tibolone to E2/NETA on the frequency of satisfactory sexual events, the frequency of sexual fantasies and subjective arousal, scores on the FSFI, FSDS, WHQ and endocrine parameters(Week 8-12 and Week 20-24 of the in-treatment period)
研究者
相似试验
终止
4 期
Investigation of Tibolone and Escitalopram in Perimenopausal DepressionPerimenopausal DepressionNCT01368068The Alfred2
已完成
2 期
Effects of Tibilone on Bone Density, Menopause Symptoms and Breast Density in Women After Prophylactic OophorectomyPostmenopausal Bone LossMenopauseBreast CancerNCT00165204Dana-Farber Cancer Institute50
已完成
不适用
To study the effectiveness of the drug tibolone in post menopausal depressioCTRI/2021/01/030776Department of psychiatry
已完成
2 期
Dose Finding Study of Danggui Buxue Tang (Herbal Formula)on the Treatment of Menopausal SymptomsPostmenopausalNCT00420576Chinese University of Hong Kong60
已完成
4 期
Tibolone and Placebo in Adjunct to Antidepressant Medication for Women With Menopausal DepressionMenopausal DepressionNCT01470092The Alfred120